Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Pharmacology and Experimental Therapeutics|March 23, 1999
Modeling geriatric depression in animals: biochemical and behavioral effects of olfactory bulbectomy in young versus aged ratsT A Slotkin, D B Miller, F Fumagalli, et al.
Occupational and Environmental Medicine|May 5, 2011
Employment and work schedule are related to telomere length in womenC G Parks, L A DeRoo, D B Miller, et al.
Journal of Lipid Research|June 5, 1999
Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-gammaS C Whitman, C A Argmann, C G Sawyez, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 14, 1999
Modification of type III VLDL, their remnants, and VLDL from ApoE-knockout mice by p-hydroxyphenylacetaldehyde, a product of myeloperoxidase activity, causes marked cholesteryl ester accumulation in macrophagesS C Whitman, S L Hazen, D B Miller, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1993
Perioperative antibiotic prophylaxis and wound infection following breast surgeryR Platt, J R Zucker, D F Zaleznik, et al.
The New England Journal of Medicine|January 18, 1990
Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgeryR Platt, D F Zaleznik, C C Hopkins, et al.
The Journal of Infectious Diseases|September 1, 1992
Prophylaxis against wound infection following herniorrhaphy or breast surgeryR Platt, J R Zucker, D F Zaleznik, et al.
Biochemical and Biophysical Research Communications|May 30, 1994
The heterologous expression and characterization of human prostaglandin G/H synthase-2 (COX-2)D B Miller, D Munster, J S Wasvary, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 16, 1998
The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigsJ R Burnett, P H Barrett, P Vicini, et al.
International Journal of Antimicrobial Agents|September 26, 2016
Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureusG Ralph Corey, Francis F Arhin, Matthew A Wikler, et al.
Pageof 15